Dr Reddy's bets on generic semaglutide, biosimilars
Reported by Economic Times Markets, not nibnow. We are not the publisher of this story, only the source is.
The company’s new generic semaglutide pens and upcoming US biosimilar launch could drive significant revenue growth after a slowdown in Revlimid sales, affecting investors and patients seeking lower‑cost options.
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
Semaglutide is a GLP‑1 drug used for diabetes and weight management, and generic versions can lower treatment costs; biosimilars are biologic medicines that are similar to existing products and expand a firm’s portfolio beyond traditional small‑molecule generics.
- •Regulatory approval and market rollout of the generic semaglutide pens in international markets
- •Overall impact of the expanded biosimilars portfolio on Dr Reddy's revenue growth